IOVA vs REPL
IOVA: Iovance delivers Amtagvi, the first FDA-approved individualized TIL cell therapy for advanced melanoma, with a pipeline expanding to lung cancer and sarcoma through centralized manufacturing and clinical innovation. REPL: Replimune is developing engineered oncolytic viruses that directly kill tumors while triggering systemic anti-tumor immunity, with its lead candidate RP1 in combination therapy for melanoma patients who have failed checkpoint inhibitors.
Side-by-side fundamentals
| Metric | IOVA | REPL | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $5.17 | $10.75 | |
| Market cap as of 2026-07-23 | $2.3B | $918M | |
| PEG as of 2026-07-23 | n/a | -0.34 | |
| Net margin as of 2026-07-23 | -123.9% | n/a | |
| Gross margin as of 2026-07-23 | +36.7% | n/a | |
| Operating margin as of 2026-07-23 | -127.2% | n/a | |
| ROE as of 2026-07-23 | -50.2% | -128.6% | IOVA higher |
| ROA as of 2026-07-23 | -38.8% | -82.3% | IOVA higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.65 | IOVA lower |
| Revenue growth (YoY) as of 2026-07-23 | +34.3% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +1388.7% | n/a | |
| Beta as of 2026-07-23 | 0.68 | 0.89 | |
| 1-year return as of 2026-07-22 close | +120.1% | +283.2% | REPL higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.